Amgen Reports New VESALIUS-CV Subgroup Results For Evolocumab In High-Risk Diabetes

Amgen reported new subgroup analyses from the phase 3 VESALIUS-CV trial for Repatha (evolocumab) in high-risk diabetes patients with elevated LDL-C. The update is supportive for the drug’s clinical profile, but the article provides no headline efficacy numbers, regulatory action, or commercial guidance. Market impact is likely limited unless follow-up data show a clearer efficacy or labeling catalyst.

Analysis

Amgen reported new subgroup analyses from the phase 3 VESALIUS-CV trial for Repatha (evolocumab) in high-risk diabetes patients with elevated LDL-C. The update is supportive for the drug’s clinical profile, but the article provides no headline efficacy numbers, regulatory action, or commercial guidance. Market impact is likely limited unless follow-up data show a clearer efficacy or labeling catalyst.